Premium Retatrutide (LY3437943) for Sale | 10mg Lyophilised Powder | ≥99% Purity | 48-Hour Delivery Across EU & UK

Retatrutide: The Revolutionary Triple Agonist Redefining Metabolic Research

Buy Retatrutide 10mg EU & UK, eupeptidelap.co.uk is proud to present Retatrutide 10mg, a premium research-grade triple agonist peptide manufactured to the highest analytical standards. As a trusted peptide vendor uk and leading EU peptide supplier, we provide researchers across Europe with Retatrutide for sale that delivers exceptional purity, consistency, and documented quality for advanced studies in metabolic regulation, obesity, and endocrine research .

Retatrutide (LY3437943) represents a groundbreaking advancement in metabolic research as the first-in-class triple agonist peptide targeting three key hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon (GCG) receptor . This sophisticated 39-amino acid synthetic peptide is engineered to harness the complementary actions of all three incretin hormones, producing unprecedented metabolic effects that surpass even the most advanced dual agonists currently available .

The molecular formula of Retatrutide is C₂₂₁H₃₄₂N₄₆O₆₈, with a molecular weight of 4731.33 g/mol . Its unique structural design includes modifications that provide resistance to enzymatic degradation and enable balanced activation of all three receptor types . In vitro studies using HEK-293 cell lines expressing human receptors demonstrate that Retatrutide exhibits potent GIP receptor agonism with an EC₅₀ of 0.0643 nM, GLP-1 receptor agonism with an EC₅₀ of 0.775 nM, and glucagon receptor agonism with an EC₅₀ of 5.79 nM . This balanced activation profile ensures that all three pathways contribute meaningfully to the compound’s metabolic effects. Buy Retatrutide 10mg EU & UK

For researchers seeking to buy peptide online EU for investigations into metabolic disorders, obesity pharmacotherapy, type 2 diabetes, or NAFLD/NASH research, eupeptidelap.co.uk offers this premium research compound with comprehensive documentation, including Certificates of Analysis and batch-specific purity data. Whether your laboratory is based in London, Berlin, Paris, or anywhere in the European Union, our guaranteed 48 hour delivery peptide service ensures your research continues without interruption. Buy Retatrutide 10mg EU & UK

The Scientific Foundation of Retatrutide Research

Mechanism of Action: Triple Receptor Activation

Retatrutide exerts its effects through simultaneous activation of three key receptors, creating synergistic actions that exceed what any single pathway could achieve alone .

GLP-1 Receptor Activation: Glucagon-like peptide-1 is an incretin hormone that helps regulate appetite and signals satiety. It stimulates insulin release, lowering blood sugar, and acts on the central nervous system to reduce appetite while slowing gastric emptying .

GIP Receptor Activation: Glucose-dependent insulinotropic polypeptide is another incretin hormone released during eating. Like GLP-1, it acts as a satiety signal and increases insulin production, while also helping regulate fat metabolism and blood sugar. Activating GIP receptors is thought to enhance the effects of GLP-1 when these two actions are combined .

Glucagon Receptor Activation: The addition of glucagon agonism is what truly distinguishes retatrutide from other metabolic peptides. While glucagon alone would raise blood sugar—potentially counteracting weight loss efforts—when activated alongside GLP-1 and GIP receptors, it increases overall energy expenditure and fat burning without excessively raising blood glucose . This novel combined mechanism means retatrutide is the first metabolic peptide to target three pathways, effectively adding an “efficient combustion engine” to the “fuel limiter” effects of GLP-1 and GIP.

Receptor Binding Profile

Receptor Type	Human EC₅₀	Binding Affinity (Ki)
GIP Receptor	0.0643 nM	0.057 nM
GLP-1 Receptor	0.775 nM	7.2 nM
Glucagon Receptor (GCGR)	5.79 nM	5.6 nM

Data demonstrates that Retatrutide exhibits approximately 8.9-fold greater potency at GIP receptors than native human GIP(1-42)-NH₂, while maintaining balanced activation across all three receptor types .

Key Research Applications

Obesity and Weight Loss Research

Retatrutide is extensively used in studies investigating body weight regulation, adipose tissue biology, and energy homeostasis . In animal models, Retatrutide (subcutaneous injection; 10 mL/kg; every 3 days for 21 days) led to significant body weight reduction and increased energy expenditure through glucagon receptor activation . The triple agonist approach leverages:

GLP-1R activation: Reduces food intake and appetite
GIPR activation: Enhances satiety signals and modulates fat distribution
GCGR activation: Increases energy expenditure and fat oxidation

Type 2 Diabetes Research

Retatrutide has demonstrated exceptional efficacy in glycemic control research . The triple agonist mechanism provides robust improvements in glucose homeostasis through multiple pathways:

Enhanced insulin secretion through GLP-1 and GIP receptor activation
Improved insulin sensitivity
Reduced glucagon secretion when blood glucose is elevated
Beneficial effects on body composition that indirectly improve glycemic control

NAFLD/NASH Research

Glucagon receptor agonism directly promotes hepatic fat oxidation and reduces de novo lipogenesis, making retatrutide uniquely positioned for NAFLD/NASH research . Preclinical studies demonstrate significant reductions in hepatic steatosis and improvements in liver enzyme profiles.

Cardiometabolic Research

Beyond weight loss, retatrutide has demonstrated significant improvements in multiple cardiovascular risk markers:

Blood Pressure Reduction: Dose-dependent decreases in both systolic and diastolic blood pressure
Lipid Profile Improvement: Reductions in triglycerides and improvements in HDL cholesterol
Inflammation Reduction: Decreases in inflammatory markers associated with metabolic dysfunction

Quality Assurance: Setting the Standard for Research Compounds

Manufacturing Excellence

eupeptidelap.co.uk sources Retatrutide 10mg from certified GMP facilities with rigorous quality control protocols:

HPLC Purity Analysis: ≥99% purity verified by high-performance liquid chromatography
Mass Spectrometry Verification: Molecular weight confirmation via LC-HRMS
Batch-Specific Certificates of Analysis: Complete documentation for each production run
Research-Use Only (RUO) Labeling: Full compliance with research compound regulations

Chemical and Product Specifications

Specification	Detail
Product Name	Retatrutide (LY3437943) – R&D Only
CAS Number	2381089-83-2
Molecular Formula	C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight	4731.33 g/mol
Amino Acid Length	39 amino acids
Purity	≥99% (HPLC verified)
Appearance	White to off-white lyophilised powder
Form	Lyophilised powder
Solubility	Soluble in DMSO (50 mg/mL); H₂O: 33.33 mg/mL with pH adjustment
Target Receptors	GLP-1R, GIPR, GCGR
Storage (Lyophilised)	-20°C to -80°C; protect from light and moisture
Storage (Reconstituted)	2-8°C for short-term; aliquot and store at -80°C for long-term
Shelf Life	2 years at -80°C; 1 year at -20°C
Shipping	Ice packs with protective packaging
Intended Use	Research and laboratory use only
Documentation	Certificate of Analysis provided with each batch

Stability and Handling Guidelines

Lyophilised Powder Storage: Store lyophilised retatrutide powder at -20°C to -80°C in a dry, dark environment, protected from light and moisture . Under proper storage conditions (argon charged, desiccated), the powder maintains stability for up to 2 years at -80°C and 1 year at -20°C .

Reconstitution Protocol:

Allow vial and solvent to reach ambient temperature before opening to prevent condensation
Reconstitute using appropriate solvent according to research protocol. Retatrutide is soluble in DMSO up to 50 mg/mL and in H₂O up to 33.33 mg/mL with pH adjustment to 7 using NaOH
Inject solvent slowly down the inside wall of the vial to minimise foaming
Gently swirl or roll the vial until fully dissolved—do not shake vigorously
Label the vial with the date of reconstitution
Refrigerate immediately at 2-8°C for short-term storage

Reconstituted Solution Storage: Store reconstituted solutions at 2-8°C for short-term use. For longer-term storage, aliquot into single-use portions and store at -80°C. Avoid repeated freeze-thaw cycles as this can degrade the peptide.

Protection from Light and Moisture:

Store in original packaging protected from light
Keep vials tightly sealed and desiccated when not in use
Allow refrigerated vials to reach room temperature before opening to prevent condensation

Key Benefits

Premium Quality Manufacturing: GMP-certified production, ≥99% HPLC-verified purity
First-In-Class Triple Agonist: Simultaneous GLP-1, GIP, and glucagon receptor activation for synergistic research applications
High Concentration: 10mg per vial—ideal quantity for targeted metabolic studies
Balanced Receptor Activation: EC₅₀ values of 0.0643 nM (GIPR), 0.775 nM (GLP-1R), and 5.79 nM (GCGR)
Superior GIP Potency: 8.9-fold greater potency than native human GIP at GIP receptors
Energy Expenditure Research: Glucagon agonism increases metabolic rate through enhanced fat oxidation
Appetite Regulation Studies: Triple mechanism targeting satiety and energy balance pathways
Hepatic Fat Research: Glucagon receptor activation promotes fat oxidation in liver tissue
Glycemic Control Studies: Balanced activation improves glucose homeostasis through multiple pathways
Body Composition Research: Investigate fat mass reduction and lean mass preservation
Cardiometabolic Research: Effects on blood pressure, lipid profiles, and inflammatory markers
Extended Stability: 2-year shelf life at -80°C with proper storage
Comprehensive Documentation: Certificates of Analysis with batch-specific purity data
48-Hour EU & UK Delivery: Rapid shipping to research facilities across Europe
Batch Consistency: Rigorous quality control ensures lot-to-lot reproducibility
EU Sourced: Available from within the European Union

Frequently Asked Questions

Q: Is Retatrutide 10mg suitable for human consumption?

A: No. Retatrutide 10mg from eupeptidelap.co.uk is strictly for research and laboratory use only . It is not for human or animal consumption, and must not be used for therapeutic, diagnostic, or clinical applications. Retatrutide is currently in Phase 3 clinical trials but has not been approved by the MHRA, EMA, or FDA for any medical use . Regulatory agencies have issued warnings against unapproved versions sold without proper RUO status . Researchers must handle this compound in accordance with institutional safety guidelines and local regulations.

Q: Is it legal to purchase retatrutide for research in the UK?

A: Retatrutide is not approved for human use by the MHRA in the UK and is not legal for sale as a medical treatment . The sale of unlicensed peptides under “research use only” labeling is permissible for legitimate research purposes when supplied to qualified buyers such as laboratories and research facilities . Products must include explicit RUO labeling and clear disclaimers that they are not for human consumption . The Medicines and Healthcare products Regulatory Agency (MHRA) may take enforcement action if marketing materials indicate personal human use .

Q: What purity level can I expect when I buy retatrutide from eupeptidelap.co.uk?

A: All Retatrutide 10mg from eupeptidelap.co.uk is tested to ≥99% purity by HPLC . Each batch is individually analyzed, and Certificates of Analysis are provided with every order, ensuring you receive material suitable for rigorous research applications.

Q: What is the mechanism of action of retatrutide?

A: Retatrutide is a first-in-class triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously . GLP-1 and GIP enhance insulin secretion, suppress appetite, and slow gastric emptying, while glucagon increases energy expenditure and promotes fat breakdown . The glucose-lowering effects of GLP-1 and GIP offset glucagon’s potential blood sugar-raising effects, creating a synergistic system .

Q: What research areas commonly use retatrutide?

A: Retatrutide is widely used in obesity and weight loss research, type 2 diabetes research, NAFLD/NASH research, cardiometabolic studies, appetite regulation research, energy expenditure studies, and body composition research .

Q: What is the molecular weight and CAS number of retatrutide?

A: Retatrutide has a molecular weight of 4731.33 g/mol and CAS number 2381089-83-2. Its molecular formula is C₂₂₁H₃₄₂N₄₆O₆₈ .

Q: How should I store retatrutide for long-term stability?

A: Store lyophilised retatrutide powder at -20°C to -80°C in a dry, dark environment, protected from light and moisture . Under proper storage conditions (argon charged, desiccated), the powder maintains stability for up to 2 years at -80°C and 1 year at -20°C . After reconstitution, store at 2-8°C for short-term use. For longer-term storage, aliquot into single-use portions and store at -80°C. Avoid repeated freeze-thaw cycles.

Q: What solvents can be used to reconstitute retatrutide?

A: Retatrutide is soluble in DMSO up to 50 mg/mL (10.57 mM) with sonication. It is soluble in H₂O up to 33.33 mg/mL (7.04 mM) with pH adjustment to 7 using NaOH .

Q: Do you ship retatrutide to EU countries?

A: Yes. As a dedicated EU peptide supplier, we ship Retatrutide 10mg to all European Union member states with our guaranteed 48 hour delivery peptide service. Our EU fulfilment centre ensures rapid delivery without customs delays. All shipments use ice packs with protective packaging to maintain compound integrity during transit .

Q: What documentation do you provide with retatrutide orders?

A: Every order includes a Certificate of Analysis (COA) with batch-specific purity data . Additional documentation, including HPLC chromatograms and mass spectrometry data, is available upon request for researchers requiring comprehensive analytical verification. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Q: What are the ongoing clinical trials for retatrutide?

A: The Phase 3 TRIUMPH and TRANSCEND clinical trial programs include multiple trials investigating retatrutide in obesity, type 2 diabetes, sleep apnea, osteoarthritis, cardiovascular outcomes, and NAFLD/NASH, with over 38 active clinical trials .

Q: Do you offer bulk quantities of retatrutide for institutional research?

A: Yes. We accommodate bulk orders for research institutions. Contact our team at sales@eupeptidelap.co.uk for volume pricing, custom requirements, and supply agreements for ongoing research programs. ...........................................

Advance Your Research with Retatrutide 10mg

eupeptidelap.co.uk is your trusted source for Retatrutide 10mg, the premium choice for researchers investigating metabolic disorders, obesity pharmacotherapy, diabetes, and metabolic dysfunction-associated steatotic liver disease. As the first-in-class triple GLP-1/GIP/glucagon receptor agonist, retatrutide represents a revolutionary tool for exploring the synergistic actions of all three incretin pathways and their unprecedented therapeutic potential .

Whether you are exploring weight loss mechanisms, designing diabetes studies, investigating hepatic steatosis, or researching cardiometabolic outcomes, our rigorously tested compound provides the quality and consistency your work demands.

Order today and experience the eupeptidelap.co.uk difference – premium quality, rapid 48-hour delivery across the EU and UK, and expert support for the European research community.

Chorzow research

Retatrutide 10mg